Behind Closed Doors - REELZChannel reelz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reelz.com Daily Mail and Mail on Sunday newspapers.
Date Time
Painting picture of breast cancer spread
A new study has shed coloured light on how an aggressive breast cancer spreads to vital organs, paving the way for more targeted drug treatments for patients.
Published today in Science Advances, the study used fluorescent proteins derived from jellyfish and sea anemones to ‘paint a picture’ of how breast cancer cells adapt and colonise other tissues, in particular the liver and lungs.
Postdoctoral Research Fellow at the Olivia Newton-John Cancer Research Institute and La Trobe University’s School of Cancer Medicine, Dr Jean Berthelet, said understanding how cancer cells travel to, and survive in, distant organs, is critical to the development of effective cancer treatments.
Advertisement
For Trine Kirkegaard Simpson and her husband Matt, 2012 should have been one of the best years of their lives.
The couple, who met backpacking before marrying in 2007, were living in Singapore and had just welcomed their second son Oliver.
Trine Kirkegaard Simpson: Don t think that it can t happen to you because sometimes I feel like what has happened to us is people s worst nightmare.
Credit:Luis Enrique Ascui
In the months following Oliverâs birth, Matt began to have subtle but increasing indigestion, bloating, stomach pain and heartburn; something that Trine said in hindsight should have raised alarms.
The young couple put it down to the stress of starting a new job and raising a young family, but when a friend pointed out Matt s excessive weight loss, Trine says she suddenly realised how tired and gaunt he appeared. It was almost as though she was looking at a stranger .
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME, Calif. (Business Wire) Humanigen, Inc.
(NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases,
today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is supported by funding from the Cure Brain Cancer Foundation. Results from the study, being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia, are expected in the first half of 2021.
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
BURLINGAME, Calif. (BUSINESS WIRE) Humanigen, Inc.
(NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases,
today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is supported by funding from the Cure Brain Cancer Foundation. Results from the study, being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia, are expected in the first half of 2021.